IL6 and COVID-19: Therefore, this systematic review will synthesize the evidence from individual case-control studies, analyze uncontrolled trials and evaluate their methods to determine whether the drug is potentially effective at reducing severe COVID-19-related mortality, thus corroborating the logic for continuing RCTs to evaluate the potential use of IL-6 inhibitors.